FDA approves KERYDIN™ (tavaborole) for toenail onychomycosis

Press Release: FDA Approves Anacor Pharmaceuticals’ KERYDIN™ (Tavaborole) Topical Solution, 5% for the Treatment of Onychomycosis of the Toenails July 08, 2014 Quote: Anacor Pharmaceuticals, Inc. (NASDAQ: ANAC) today announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application for KERYDIN™ (tavaborole) topical solution, 5%, the first oxaborole antifungal approved for the topical treatment of onychomycosis of the toenails

More:
FDA approves KERYDIN™ (tavaborole) for toenail onychomycosis

Previous post:

Next post: